Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC.

JTO Clin Res Rep · 2021 · PMC8474390 · PMID 34590042

Europe PMC DOI

hedged sentence

0.0580

closest p · 1.2× alpha

0.0580

boldest claim

The sentences

did not reach statistical significancep = 0.058so close (0.05 < p ≤ 0.1)

Durvalumab treatment duration, when assessed as a continuous variable, did not reach statistical significance in association with OS (hazard ratio = 0.49, [0.24–1.03], p = 0.058) ( Table 3 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.